Find the latest pharmaceutical market place for APIs enquiry about Molnupiravir on PharmaCompass.com.

india-flag Flag

Molnupiravir API needed in India [ENA16057]

A company that focuses on the research and development of OSDs, oral liquids, injectables, ointments & creams is looking for suppliers of Molnupiravir API. The suppliers must support this enquiry with CoA.

Reply

11 Jan 2023

Molnupiravir API needed in Iran [ENA13635]

A company that specializes in R&D and manufacturing of solid dosage forms is looking for suppliers of Molnupiravir API for commercial purpose. The suppliers must support this enquiry with CoA.

Reply

14 May 2022

india-flag Flag

Molnupiravir (5 kg) API needed in India [ENA12348]

A privately owned, rapidly growing pharmaceutical company that is engaged in the acquisition, licensing, development (ANDA), sales, marketing & distribution of generic pharmaceuticals, drugs, and OTC products is looking for suppliers of Molnupiravir (5 kg) API for the formulation of capsules. The suppliers must support this enquiry with CoA.

Reply

08 Jan 2022

india-flag Flag

BP Grade Molnupiravir API needed in India [ENA12296]

A company that deals in the development & manufacturing of finished formulations is looking for suppliers of BP Grade Molnupiravir API. The initially required quantity is 10 kg - 20 kg for development & later 1 MT - 2 MT per month for commercial purpose.

Reply

04 Jan 2022

india-flag Flag

Various APIs needed in India [ENA12037]

A company that deals in the research, development & manufacturing of finished products is looking for suppliers of Various APIs for development purpose.
1. Molnupiravir (500 g - 1 kg) API
2. Oseltamivir Phosphate (500 g - 1 kg) API
3. Teneligliptin (200 g - 500 g) API
4. Ticagrelor (400 g - 600 g) API

Reply

07 Dec 2021

Molnupiravir API needed in Egypt [ENA11984]

A company that deals in various pharmaceutical products including hard gelatin capsules, tablets and dietary supplements is looking for suppliers of Molnupiravir API for both development & commercial purpose. The suppliers must support this enquiry with valid GMP & CoA.

Reply

02 Dec 2021

Molnupiravir (MOQ) API needed in Iran [ENA11391]

A company that deals in the development & manufacturing of modern medical products is looking for suppliers of Molnupiravir (MOQ) API for both development & commercial purpose. The suppliers must support this enquiry with CoA.

Reply

14 Sep 2021

Molnupiravir (100 kg) API needed in China [ENA11249]

Guangzhou Biodelta Technology, a company that deals in the distribution of various pharmaceutical products is looking for suppliers of Molnupiravir (100 kg) API for commercial purpose. The suppliers must support this enquiry with CoA. Interested suppliers can contact them via their email: jiewen5164@163.com.

Reply

31 Aug 2021

Molnupiravir API needed in Iran [ENA11137]

A company that deals in the R&D and commercialization of a wide range of pharmaceutical products is looking for suppliers of Molnupiravir API for development purpose. The suppliers must support this enquiry with CTD Dossier & CoA.

Reply

17 Aug 2021

india-flag Flag

Various APIs needed in India [ENA10605]

A pharmaceutical company that focuses on general products, Beta-Lactum/ Cephalosporins in the form of tablets, capsules, liquid-orals, ointments, creams, lotions and powdered injections is looking for suppliers of Various APIs for development purposes. The suppliers must support this enquiry with CoA.
1. BP/ USP Grade Butorphanol Tartrate (30 g) API
2. USP Grade Fluoxetine (250 g) API
3. In-house/ USP Grade Ulinastatin (100 g) (245 Miu) API
4. In-house Grade Molnupiravir (1.50 kg) API

Reply

10 Jun 2021

india-flag Flag

Molnupiravir API needed in India [ENA09658]

A company that deals in pharmaceutical intermediates, speciality chemicals, impurities and active pharmaceutical ingredients is looking for suppliers of Molnupiravir API. The initial required quantity is 5 g for development purposes and later 200 g - 500 g for commercial manufacturing purposes. The final market is India and the US/ EU.

Reply

05 Feb 2021